Treatment
SAL0140 clinical trials
We’re tracking 2 recruiting studies that include SAL0140, each written for real people, not researchers, below.
Recruiting studies
- NCT07051603RecruitingPhase 1
Safety study of SAL0140 in healthy Chinese adults
This study tests the safety and how the body handles a new medicine (SAL0140) in healthy people. It helps doctors find the right dose and check for side effects.
Guangzhou, GuangdongAges 18–65 - NCT07654140RecruitingPhase 2
Testing a new drug for uncontrolled high blood pressure
This trial tests a new drug called SAL0140 for people whose high blood pressure is not controlled by current treatments. It may help lower blood pressure when other medications haven't worked well enough.
Beijing, Beijing MunicipalityAges 18–75
What SAL0140 is being studied for
Conditions with recruiting SAL0140 studies.
Common questions
- Are there clinical trials studying SAL0140?
- Yes. Clin2 currently lists 2 recruiting studies that include SAL0140, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a SAL0140 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is SAL0140 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether SAL0140 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.